Skip to content

One-quarter died on HIV treatment waiting list in South Africa's Free State province

Maraviroc showing tantalising promise as microbicide in preclinical studies

ACTG 5202: No significant difference in time to failure between Kivexa and Truvada in patients with lower viral loads when paired with efavirenz or atazanavir

New CCR5 antagonist TBR-652 shows good antiviral activity in early study

Elvitegravir 'Quad' pill performs well, new booster cobicistat works as well as ritonavir

CCR5 antagonist vicriviroc fails to surpass potent background regimen

Once-daily darunavir effective and less toxic than twice-daily in experienced patients without prior darunavir resistance: ODIN

XDR TB emerging despite good adherence, due to sub-optimal treatment and bad infection control

Even very low levels of pre-existing resistance increase risk of efavirenz failure